Pacira BioSciences (PCRX) director receives 6,163 restricted stock units in equity grant

Rhea-AI Filing Summary

Pacira BioSciences director Mark A. Kronenfeld received an equity award of 6,163 restricted stock units on June 11, 2025. The grant was at no cash cost per share and increases his direct holdings to 31,065 common shares equivalents.

The units vest on June 11, 2026, only if he remains in continuous service with Pacira through that date. Each restricted stock unit converts into one share of Pacira common stock upon vesting, reflecting standard, service-based director compensation rather than an open-market purchase or sale.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Kronenfeld Mark A.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	6,163	$0.00	--

Holdings After Transaction: Common Stock — 31,065 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kronenfeld Mark A.

(Last) (First) (Middle)

C/O PACIRA BIOSCIENCES, INC.

2000 SIERRA POINT PARKWAY, SUITE 900

(Street)

BRISBANE CALIFORNIA 94005

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Pacira BioSciences, Inc. [ PCRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2025

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)
06/13/2025

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/11/2025		A		6,163(1)	A	$0	31,065	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted stock units that vest on June 11, 2026, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.

Remarks:

The Form 4, as originally filed, inadvertently reported a grant of 9,999 restricted stock units instead of 6,163 restricted stock units.

	/s/ Kristen Williams, Attorney-in-Fact	03/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Pacira BioSciences (PCRX) report for Mark A. Kronenfeld?

Pacira BioSciences reported that director Mark A. Kronenfeld received 6,163 restricted stock units as an equity award. The grant was made on June 11, 2025 at no cash cost, reflecting stock-based compensation rather than an open-market trade in Pacira’s common shares.

When do Mark A. Kronenfeld’s new Pacira (PCRX) restricted stock units vest?

The 6,163 restricted stock units granted to Mark A. Kronenfeld vest on June 11, 2026. Vesting is contingent on his remaining in continuous service with Pacira BioSciences through that date, making this a time-based compensation award tied to ongoing board service.

How many Pacira (PCRX) shares does Mark A. Kronenfeld hold after this grant?

Following the June 11, 2025 award, Mark A. Kronenfeld holds 31,065 Pacira common stock equivalents directly. This total includes the newly granted 6,163 restricted stock units, each representing the right to receive one share of common stock when the award vests.

Does Mark A. Kronenfeld’s Pacira (PCRX) award involve any purchase price?

No cash purchase price is associated with this award to Mark A. Kronenfeld. The transaction code "A" and zero price per share indicate a stock-based grant, where 6,163 restricted stock units are provided as compensation rather than through a market purchase of Pacira shares.

What does each restricted stock unit in Pacira (PCRX) represent for Mark A. Kronenfeld?

Each restricted stock unit granted to Mark A. Kronenfeld represents the contingent right to receive one share of Pacira common stock. The units convert into shares only upon vesting on June 11, 2026, assuming he maintains continuous service with the company until that date.